From the Office of Laboratory Animal Welfare National Institutions of Health Department of Health and Human Services. Modified from original found at NIH website.
The section of grant applications, contract proposals and cooperative agreements where you must describe the use of animals in your work.
You must provide a VAS if your work involves the use of live vertebrate animals, including generating custom antibodies and obtaining tissues from live vertebrate animals.
You will need to address all the criteria of the VAS for each performance site.
These requirements, as applicable, will take effect for all grant applications except Fellowship (F series) and Training (T series) grants for due dates on or after January 25, 2016, and will take effect for all applications for due dates on or after May 25, 2016. For more detailed information regarding the changes, please visit the official announcement here.
Modified for Tufts and Tufts Medical Center IACUC protocols. Original found at NIH website.
Typically, all of the required elements for the VAS can be addressed within 1-2 pages. The VAS must not be used to circumvent page limits. Applicants should be aware that NIH may release information contained in funded applications pursuant to a Freedom of Information Act request.
NOTE: The text in orange directs you to the section of the IACUC animal protocol where you can find the relevant information to address the question. Please note that the information may additionally be found in other sections. If you need assistance locating the relevant information in a protocol, you can contact the IACUC office.
Investigators must include a concise, complete description of the proposed procedures. While additional details may be included in the Research Strategy, a coherent, albeit brief, description of the proposed use of the animals must be provided in the VAS. The description must include sufficient detail to allow evaluation of the procedures.
Examples of the types of procedures that may be described include:
In describing the animals, investigators must provide the following information:
If procedures (e.g., pharmacological, surgical) might lead to severe discomfort, distress, pain or injury, indicators for humane endpoints and euthanasia (e.g., severe infection, respiratory distress, failure to eat, tumor size) may be described. (Section IX B) All of these issues are particularly important for survival surgeries (Section X B).
If multiple surgeries are proposed, these should be well justified and provisions to avoid any potential complications may be described (Section VII, or if multiple MAJOR surgeries proposed, justified in Section V#1).
Investigators should state whether euthanasia will be performed and indicate if the method of euthanasia is consistent with AVMA guidelines. If consistent, no further information is needed. If it isn’t consistent, they must describe the method of euthanasia and provide scientific justification. (Section XII)
Aims 1-3 will be addressed in vitro; Aim 4 will be addressed using a mouse model of ocular infection.